The U.S. Food and Drug Administration (FDA) yesterday approved asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze™) as a component of a chemotherapy regimen used to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in patients who are allergic to other commonly used asparaginase products. ALL is the most common type of childhood cancer, with nearly 3,000 new cases diagnosed each year in the U.S.
The 2021 American Society of Clinical Oncology (ASCO) Annual Meeting took place last week. ASCO brings together the cancer community to explore the latest advancements in research, treatment and patient care.
The theme of this year's meeting was “Equity: Every Patient. Every Day. Everywhere.” We were particularly gratified to see this topic because as a patient-focused organization, The Leukemia & Lymphoma Society (LLS) stands for all cancer patients, working to ensure they have access to quality affordable care.
In honor of Asian American and Pacific Islander Heritage Month in May, LLS is highlighting the stories of volunteers, healthcare professionals, researchers, patients, survivors, and advocates from across our community. Recently, we caught up with Charlene Liao, Ph.D., Co-Founder, President, and CEO of Immune-Onc Therapeutics, a new LLS Therapy Acceleration Program® (LLS TAP) partner.
In this Q&A, we are highlighting Dr. Christopher R. Flowers, MD, chair of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center and LLS National Board Member. Later this week, Dr. Flowers will be speaking on a timely panel about diversity in hematology clinical trials at AACR 2021.